EW Healthcare Partners - Portfolio - Catalyst Biosciences, Inc.

Catalyst Biosciences, Inc.

Develops therapeutics for hemophilia and inflammatory diseases

Completed reverse merger with Targacept in August 2015
Catalyst is the surviving public entity now trading on the NASDAQ as "CBIO"
Lead product, a Factor VIIa drug candidate for hemophilia, has successfully completed Phase I trials
Catalyst is well-capitalized to advance its hemophilia drug into pivotal clinical trials